Send us a text

In this episode of the Life Science Success podcast my guest is Jeremy Stackawitz.  Jeremy has over 25 years of healthcare industry experience and 15 years of diagnostics experience. Before joining Senzo as CEO, from 2009-2021 Mr. Stackawitz held roles of CCO, President, and CEO at Quotient (QTNT), helping lead the company from start-up to IPO. 

 

Jeremy Stackawitz, CEO of Senzo Biosciences, recently discussed the current state of the diagnostic industry. The industry faces several challenges and opportunities, including the need for accessibility and cost reduction. Stackawitz notes that the COVID-19 pandemic has had a significant impact on the industry, with many companies struggling to stay afloat.

One of the key topics Stackawitz discussed was the advantages and disadvantages of small versus large companies in the industry. While smaller companies may have more agility and flexibility, larger companies may have more resources and established relationships with key players in the industry.

When asked to share his favorite leadership advice, Stackawitz emphasized the importance of building a strong team and fostering a culture of collaboration and innovation. He also shared what inspires and concerns him in his work, including the potential to make a positive impact on people's lives through improved diagnostics, as well as the challenges of navigating a complex and constantly evolving industry.

Overall, Stackawitz's insights provide a valuable perspective on the diagnostic industry and the opportunities and challenges it faces. By addressing issues such as accessibility, cost reduction, and the advantages and disadvantages of different types of companies, the industry can continue to innovate and improve the lives of people around the world.